Dahl, Matthias

[["dc.bibliographiccitation.firstpage","85"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Medical Ethics"],["dc.bibliographiccitation.lastpage","87"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Lenk, C."],["dc.contributor.author","Radenbach, K."],["dc.contributor.author","Dahl, Matthias"],["dc.contributor.author","Wiesemann, Claudia"],["dc.date.accessioned","2017-10-16T10:54:28Z"],["dc.date.available","2017-10-16T10:54:28Z"],["dc.date.issued","2004"],["dc.description.abstract","Objectives: Clinical trials in humans in Germany—as in many other countries—must be approved by localresearch ethics committees (RECs). The current study has been designed to document and evaluatedecisions of chairpersons of RECs in the problematic field of non-therapeutic research with minors. Theauthors’ purpose was to examine whether non-therapeutic research was acceptable for chairpersons atall, and whether there was certainty on how to decide in research trials involving more than minimal risk.Design: In a questionnaire, REC chairpersons had to evaluate five different scenarios with (in parts) nontherapeuticresearch. The scenarios described realistic potential research projects with minors, involvingincreasing levels of risk for the research participants. The chairpersons had to decide whether therespective projects should be approved.Methods: A total of 49 German REC chairpersons were sent questionnaires; 29 questionnaires werereturned. The main measurements were approval or rejection of research scenarios.Results: Chairpersons of German RECs generally tend to accept non-therapeutic research with minors ifthe apparent risk for the participating children is low. If the risk is clearly higher than ‘‘minimal’’, thechairpersons’ decisions differ widely.Conclusion: The fact that there seem to be different attitudes of chairpersons to non-therapeutic researchwith minors is problematic from an ethical point of view. It suggests a general uncertainty about thestandards of protection for minor research participants in Germany. Therefore, further ethical and legalregulation of non-therapeutic research with minors in Germany seems necessary."],["dc.format.mimetype","application/pdf"],["dc.identifier.doi","10.1136/jme.2003.005900"],["dc.identifier.fs","17497"],["dc.identifier.gro","3146746"],["dc.identifier.pmid","14872082"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4135"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/9420"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","final"],["dc.relation.issn","0306-6800"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject","REC, research ethics committee"],["dc.subject.ddc","610"],["dc.title","Non-therapeutic research with minors: how do chairpersons of German research ethics committees decide?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dc.type.version","submitted_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Advances in Condensed Matter Physics"],["dc.bibliographiccitation.lastpage","11"],["dc.bibliographiccitation.volume","2018"],["dc.contributor.author","Wallenhorst, L."],["dc.contributor.author","Rerich, R."],["dc.contributor.author","Vovk, M."],["dc.contributor.author","Dahle, S."],["dc.contributor.author","Militz, H."],["dc.contributor.author","Ohms, G."],["dc.contributor.author","Viöl, W."],["dc.date.accessioned","2019-07-09T11:45:04Z"],["dc.date.available","2019-07-09T11:45:04Z"],["dc.date.issued","2018"],["dc.description.abstract","This study investigated themorphologic and chemical properties of coatings based on PMMA/ATH powder and deposited by cold plasma spraying on wood and glass. Since the deposition of pure PMMA/ATH powder with air as process gas yielded coatings with insufficient abrasion resistance, two modifications of the basic process were investigated. Previous studies showed that replacing air as process gas with forming gas did not enhance the abrasion resistance, but the addition of a phenol-formaldehyde resin (PF) succeeded in stabilising the particle coatings. In thiswork, results frommorphologic and chemical analysis suggestedanencasement of the PMMA/ATH particles by plasma-modified PF and thus a fusion of individual particles, explaining the enhanced bonding. Moreover, adhesion tests confirmed an outstanding bonding between the coating and wood as well as glass, which is assumed to result from interactions between the PF’s hydroxyl groups and functional groups on the substrates’ surfaces. Studies on the wettability revealed a hydrophobic character of such coatings, therefore generally indicating a possible application, for example, to reduce water uptake by wooden materials."],["dc.identifier.doi","10.1155/2018/3539417"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59155"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1687-8124"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","570"],["dc.title","Morphologic and Chemical Properties of PMMA/ATH Layers with Enhanced Abrasion Resistance Realised by Cold Plasma Spraying at Atmospheric Pressure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","123"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Neuroinflammation"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Hahn, S."],["dc.contributor.author","Trendelenburg, G."],["dc.contributor.author","Scharf, M."],["dc.contributor.author","Denno, Y."],["dc.contributor.author","Brakopp, S."],["dc.contributor.author","Teegen, B."],["dc.contributor.author","Probst, C."],["dc.contributor.author","Wandinger, K. P"],["dc.contributor.author","Buttmann, M."],["dc.contributor.author","Haarmann, A."],["dc.contributor.author","Szabados, F."],["dc.contributor.author","vom Dahl, M."],["dc.contributor.author","Kümpfel, T."],["dc.contributor.author","Eichhorn, P."],["dc.contributor.author","Gold, H."],["dc.contributor.author","Paul, F."],["dc.contributor.author","Jarius, S."],["dc.contributor.author","Melzer, N."],["dc.contributor.author","Stöcker, W."],["dc.contributor.author","Komorowski, L."],["dc.date.accessioned","2019-07-09T11:43:25Z"],["dc.date.available","2019-07-09T11:43:25Z"],["dc.date.issued","2017"],["dc.description.abstract","Abstract Background Autoantibodies, in particular those against aquaporin-4 and myelin-oligodendrocyte glycoprotein (MOG), aid as biomarkers in the differential diagnosis of demyelination. Here, we report on discovery of autoantibodies against flotillin in patients with multiple sclerosis (MS). Methods The target antigen was identified by histo-immunoprecipitation using the patients’ sera and cryosections of rat or pig cerebellum combined with mass spectrometrical analysis. Correct identification was ascertained by indirect immunofluorescence and neutralization tests using the target antigens recombinantly expressed in HEK293 cells. Results Serum and CSF of the index patient produced a fine-granular IgG indirect immunofluorescence staining of the hippocampal and cerebellar molecular layers. Flotillin-1 and flotillin-2 were identified as target autoantigens. They also reacted with recombinant human flotillin-1/2 co-expressed in HEK293 cells, but not with the individual flotillins in fixed- and live-cell assays. Moreover, neutralization using flotillin-1/2, but not the single flotillins, abolished the tissue reactivity of patient serum. Screening of 521 patients, for whom anti-aquaporin-4 testing was requested and negative, revealed 8 additional patients with anti-flotillin-1/2 autoantibodies. All eight were negative for anti-MOG. Six patients ex post fulfilled the revised McDonald criteria for MS. Vice versa, screening of 538 MS sera revealed anti-flotillin-1/2 autoantibodies in eight patients. The autoantibodies were not found in a cohort of 67 patients with other neural autoantibody-associated syndromes and in 444 healthy blood donors. Conclusions Autoantibodies against the flotillin-1/2 heterocomplex, a peripheral membrane protein that is involved in axon outgrowth and regeneration of the optic nerve, are present in 1–2% of patients with bona fide MS."],["dc.identifier.doi","10.1186/s12974-017-0900-z"],["dc.identifier.pmid","28645295"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14513"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58882"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]